10:36 AM EST - Abattis Bioceuticals Corp. : Northern Vine Labs, a subsidiary of Emerald Health Therapeutics Inc. (TSXV:EMH) (OTCQX:EMHTF) and Abattis Bioceuticals Corp. (CSE:ATT) (OTC:ATTBF), today announced that Health Canada has approved an amendment to the Company’s dealer’s license. The license amendment provides the Company the ability to transport, deliver and sell product to other Licensed Dealers (LD), authorized persons under the Controlled Drug and Substance Act (CDSA), and Licensed Producers (LP). Along with the Company’s already authorized activities for analytical testing, extraction, and import/export, this amendment also allows Northern Vine Labs to broaden its business opportunities through the production and sale of downstream cannabis products. Abattis Bioceuticals Corp.
shares ATT:CNX are trading up 8 cents at $0.58.
